Clinical Trial

A Mobile Web App Intervention to Promote Cervical Cancer Screening

Study acronym: wPap
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The overarching goal of this study is to increase cervical cancer (CC) screening rates among Indigenous women in the U.S. Specifically, the study aims to develop and evaluate a culturally tailored, multilevel, multimedia mobile web app intervention (wPap) for women of the Yankton Sioux Tribe (YST) living on the YST Reservation in South Dakota. The wPap intervention will be tested in a randomized clinical trial (RCT) involving 120 YST women aged 25-65. Participants will be randomly assigned to either: (a) the wPap intervention group (n = 60), receiving personalized, culturally tailored multilevel multimedia messages through a mobile web app along with health navigator support, or (b) a waitlist control group (n = 60), receiving printed educational materials on cervical cancer and screening guidelines along with health navigator support. The intervention will last seven days, with assessments conducted at baseline, one week post-intervention, and six months post-intervention via surveys and telephone follow-up. The study tests the following hypotheses: (H1) women in the wPap intervention group will achieve higher CC screening rates than the waitlist control group; (H2) the wPap group will demonstrate greater improvements in knowledge, attitudes/beliefs, self-efficacy, and intention to undergo CC screening; and (H3) the wPap group will report higher satisfaction and acceptance of the intervention compared with the waitlist control group. Findings will inform the feasibility, acceptability, and efficacy of mobile web app interventions tailored to Indigenous communities to improve CC screening.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-01.
Trial Details
NCT Number NCT07574190
Lead Sponsor University of South Dakota
Conditions Cervical Cancer Screening
Enrollment 120 participants
Start Date 2026-05
Primary Completion 2026-11 (estimated)
Study Completion 2026-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-22